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Effect of VCP modulators on gene 
expression profiles of retinal 
ganglion cells in an acute injury 
mouse model
Tomoko Hasegawa1, Hanako Ohashi ikeda1*, Norimoto Gotoh1, Kei iida2, Sachiko iwai1, 
Noriko nakano1, Akira Kakizuka3 & Akitaka tsujikawa1
In glaucoma, retinal ganglion cells are damaged, leading to the progressive constriction of the visual 
field. We have previously shown that the valosin-containing protein (VCP) modulators, Kyoto University 
Substance (KUS)121 and KUS187, prevent the death of retinal ganglion cells in animal models of 
glaucoma, including the one generated by N-methyl-D-aspartate (NMDA)-induced neurotoxicity. 
KUSs appeared to avert endoplasmic reticulum (ER) stress by maintaining ATP levels, resulting in the 
protection of ganglion cells from cell death. To further elucidate the protective mechanisms of KUSs, we 
examined gene expression profiles in affected ganglion cells. We first injected KUS-treated mice with 
NMDA and then isolated the affected retinal ganglion cells using fluorescence-activated cell sorting. 
Gene expression in the cells was quantified using a next-generation sequencer. Resultantly, we found 
that KUS121 upregulated several genes involved in energy metabolism. In addition, we observed the 
upregulation of Zfp667, which has been reported to suppress apoptosis-related genes and prevent cell 
death. These results further support the suitability of KUS121 as a therapeutic drug in protecting retinal 
ganglion cells in ophthalmic disorders, such as glaucoma.
Glaucoma is one of the leading causes of blindness around the world1–4. In this disease, retinal ganglion cells are 
damaged followed by progressive visual field constriction5,6. The most commonly used evidenced treatment for 
glaucoma involves reducing intraocular pressure with drugs or surgery, and it effectively slows the deterioration 
of visual function7–9. While high intraocular pressure and age are known risk factors for glaucoma progression10, 
the possible involvement of myopia and blood flow impairment remain controversial10–14, thus, the glaucoma 
pathologies are not fully understood.
We have previously synthesised novel compounds, Kyoto University Substances (KUSs), which mitigate cellu-
lar ATP reduction by modulating the ATPase activity of valosin-containing protein (VCP)15, the most abundant 
soluble ATPase in the cell. KUSs prevented ATP depletion, endoplasmic reticulum (ER) stress, and consequently 
cell death in cultured cells. KUSs consistently suppressed retinal neuronal cell death in animal models of ocular 
diseases, such as retinitis pigmentosa15,16, glaucoma17, and central retinal artery occlusion18.
Intravitreous injection of N-methyl-D-aspartate (NMDA) induces neurotoxicity mainly in retinal ganglion 
cells19. Administration of KUSs prevented the decrease of the retinal ganglion cells and nerve fibers, in the acute 
retinal injury model induced by NMDA17. In addition to the suppression of the decrease of ATP levels, we aimed 
to clarify the potential involvement of cellular genes by the KUS treatment. Towards this end, isolation and collec-
tion of retinal ganglion cells is needed because they consist of only a small proportion of retinal cells20. A two-step 
immunopanning and magnetic separation21–24, or combined immunopanning-magnetic separation25 have been 
used to isolate retinal ganglion cells previously26–28. The use of fluorescence-activated cell sorting (FACS) is 
another way to collect the retinal ganglion cells. These methods allow us to isolate fresh ganglion cells for RNA 
analyses, which faithfully reflect the in vivo state. Thy1-CFP transgenic mice29 (referred hereafter as Thy1-CFP 
mice) express cyan fluorescent protein (CFP) in the retinal ganglion cells30 under the Thy1 promoter31,32, which 
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enabled us to purify retinal ganglion cells by FACS. Next, we used next-generation sequencing technologies33 to 
compare gene expression profiles between with and without KUS treatments.
Results
mRNA expression of key genes was significantly altered 4 h after NMDA injection. To decide 
the timing for evaluation of gene expression after intravitreous NMDA injection, the mRNA levels of 18 genes, 
of which some were reported to be upregulated after NMDA injection and some could be influenced by admin-
istration of KUSs, were analysed using quantitative reverse transcription polymerase chain reaction (qRT-PCR). 
The former were v-rel reticuloendotheliosis viral oncogene homolog A (Rela), caspase 3 (Casp3), nuclear factor 
of kappa light polypeptide gene enhancer in B cells inhibitor - alpha (Nfkbia), interleukin 6 (Il6), FBJ osteosar-
coma oncogene (Fos), mitogen-activated protein kinase (Mapk)1, Mapk3, Mapk10, jun proto-oncogene (Jun), 
tumor necrosis factor (Tnf), and high mobility group box 1 (Hmgb1) and the latter were serine/threonine-pro-
tein kinase (Akt)1, Akt2, mitochondrial fission 1 (Fis1), mitofusin (Mfn)1, Mfn2, dynamin 1-like (Dnm1l), optic 
atrophy 1 (Opa1). Jun and Fos, which were reported to be immediately upregulated following external stimuli34 
increased 2 h after the NMDA injection (Fig. 1). Expression of Rela and Casp3 (a downstream effector of apopto-
sis) increased prominently 6 h after the injection (Fig. 1). In contrast, expression of the other 14 genes including 
Nfkbia, Tnf, and Il-6 increased notably 4 h after the NMDA injection (Fig. 1). Therefore, we decided to evaluate 
the effect of KUSs on the gene expression profiles 4 h after the NMDA injection.
Purification of retinal ganglion cells by FACS. To study the effects of the KUSs on the affected cells, 
we first isolated the CFP expressing retinal ganglion cells from dissociated whole neural retina of Thy1-CFP 
mice using FACS. The CFP-positive cells were found to account for 0.04–0.12% of all retinal cells (Fig. 2a, area 
Figure 1. Relative mRNA expression at different time points after intravitreal N-methyl-D-aspartate 
(NMDA) injection. Neural retinas were analysed 2, 4 and 6 h after intravitreal NMDA (5 nmol) injection. 
The relative expression levels of (a) jun proto-oncogene (Jun), (b) FBJ osteosarcoma oncogene (Fos), (c) v-rel 
reticuloendotheliosis viral oncogene homolog A (Rela), (d) capsase-3 (Casp3), (e) nuclear factor of kappa 
light polypeptide gene enhancer in B cells inhibitor, alpha (Nfkbia), (f) tumor necrosis factor (Tnf) and (g) 
interleukin 6 (Il6) mRNA were analysed by qRT-PCR. The ratios of mRNA expression of each gene to that of 
actin were calculated. The ratios to actin at 2 h, 4 h and 6 h were divided by those at 0 h.
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1); no CFP-positive cells were observed in the retina of wild-type mice (Fig. 2b). Retinal cells expressing both 
brain-specific homeobox/POU domain protein 3A (Brn3a) and paired box protein (Pax) 6 are defined as reti-
nal ganglion cells. By immunostaining the dissociated cells, we confirmed that Brn3a- and Pax6-positive retinal 
Figure 2. Analysis of dissociated retinal cells and sorted cells by flow cytometry. Retinal cells were analysed 
using fluorescence-activated cell sorting. The x-axis shows fluorescent of PerCP-Cy5 to detect 7-Amino-
Actinomycin D (7-AAD) fluorescence which labels dead cells and the y-axis shows fluorescence of AmCyan-A 
to detect cyan fluorescent protein (CFP) fluorescence. (a) Analysis of dissociated retinal cells of Thy1-CFP mice 
which manifest CFP in retinal ganglion cells. Cells which possess relatively strong CFP fluorescent without 
7-AAD fluorescence, whose CFP fluorescence was considered not to be autofluorescence, were contained in 
the area 1 (0.04–0.12% of total cells). (b) Analysis of dissociated retinal cells of wild-type mice. No cells were 
contained in the area 1 (CFP-positive). (c) Re-analysis of the sorted cells by gate RGCs (see Method and Fig. S1). 
88.9–93.4% of the sorted cells were included in area 1 (CFP-positive). (d) The sorted cells were stained with 
anti-brain-specific homeobox/POU domain protein 3A (Brn3a, green) and anti- paired box genes 6 (Pax6, red) 
antibodies. Nuclei were counter stained with 4’,6-diamidino-2-phenylindole (DAPI, blue). Scale bar: 50 µm. 
(e) mRNA expression of synaptosomal-associated protein 25 (Snap25), tubulin, beta 3 class III (Tubb3), RNA 
binding protein with multiple splicing (Rbpms) and rhodopsin (Rho) in cells sorted by gate RGCs or gate PR 
(see Methods and Supplementary, Fig. S1b) were visualised with the Integrated Genome Browser. Snap25, 
Tubb3 and Rbpms were highly expressed in Gate RGCs and not in Gate PR while Rho was highly expressed in 
Gate PR and not in Gate RGCs (black arrows). RGC: retinal ganglion cell, PR: photoreceptors.
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ganglion cells accounted for 0.01–0.12% of the total retinal cells. The percentage of the retinal ganglion cells esti-
mated with the immunocytochemical analysis was almost the same as the FACS analysis.
FACS from 2 retinas of 2 Thy1-CFP mice enabled us to sort 1,494–3,550 CFP-positive cells (see method 
and Fig. S1, gate RGCs) in 30–50 min, which was considered sufficiently fast to collect fresh cells to analyze 
mRNA expression. Re-analysis of the sorted cells showed that 88.9–93.4% of the cells were CFP-positive, which 
indicates that the FACS sorting effectively collected and concentrated the CFP-positive retinal cells (Fig. 2c). 
Immunostaining of the sorted cells showed that almost all the sorted cells were Brn3a- and Pax6-positive and 
were retinal ganglion cells (Fig. 2d and Fig. S2). To confirm that the collected cells were indeed retinal gan-
glion cells, their mRNAs were visualised with the Integrated Genome Browser35. We confirmed expected mRNA 
expression profiles: high expression of synaptosomal-associated protein (Snap25)36, and tubulin, beta 3 class III 
(Tubb3), which are expressed in neuronal cells and RNA binding protein with multiple splicing (Rbpms)37, which 
is expressed in retinal ganglion cells and low expression of rhodopsin (Rho), which is expressed in rod photore-
ceptors. These results further validated our FACS sorting protocol (Fig. 2e, gate RGCs in Fig. S1). Consistent with 
the above, CFP-negative cells collected by gate PR in Fig. S1, expressed high Rho levels without Snap25, Tubb3, 
and Rbpms expression, indicating that they contained rod photoreceptors and not ganglion cells (Fig. 2e, gate PR). 
From these data, we assumed the CFP-positive cells sorted by FACS, successfully enriched retinal ganglion cells 
and were suitable for the next experiments.
mRNAs related to gene expression and energy metabolism were upregulated in KUS-treated 
retinal ganglion cells. Using analysis of variance (ANOVA), 255 genes showed significant (P < 0.01) expres-
sion changes among four conditions; non-treatment (non-treat), vehicle with intravitreous injection of NMDA 
(NMDA-saline), KUS121 treatment with intravitreous injection of NMDA (KUS121), and KUS187 treatment 
with intravitreous injection of NMDA (KUS187) (Supplementary Table S1). Hierarchical clustering analyses of 
the 255 genes distributed samples between the conditions (Fig. 3a,b). Hierarchical clustering analyses of the 
ANOVA-passed genes revealed that ANOVA successfully selected genes that distinguish each condition (Fig. 3a). 
Moreover, the samples of the three experimental repeats showed similar patterns of upregulated and downreg-
ulated genes on heatmap (Fig. 3b). These results showed that the experimental repeats displayed great repro-
ducibility of the gene expression profiles within each condition. While some genes showed similar expression 
patterns between the NMDA-saline and KUSs-treated groups, other genes showed clearly differential expression 
patterns (Fig. 3b). KUSs-treated groups were clearly separated from saline-treated groups. These data indicated 
the KUSs-treated groups have characteristic gene expression profiles distinct from the non-treat or NMDA-saline 
groups.
Gene ontology (GO) analysis38 was performed to annotate genes into biological ontology. After X-means 
clustering, genes in hyper cluster A and B were analyzed (Supplementary Fig. S3). Genes in hyper cluster A were 
found to be associated with 31 GO terms, which included RNA metabolic processes, biosynthetic processes, gene 
expression and metabolic processes (Table 1, Supplementary Table S2) while genes in hyper cluster B were not 
associated with enrichment of any GO terms.
Pathway analysis39,40 showed 4 statistically significant pathways which were common in 
NMDA-saline < non-treat pathways, KUS121 > NMDA-saline pathways and KUS187 > NMDA-saline pathways 
(Table 2). The activated pathways included the glycogen metabolism pathway (Fig. 4). There were 7 statistically 
significant pathways which were common in NMDA-saline > non-treat pathways, KUS121 < NMDA-saline path-
ways and KUS187 < NMDA-saline pathways (Table 3).
Zfp667 was upregulated in KUS121-treated retinal ganglion cells. We next performed literature 
search on the functions of the 255 genes whose mRNA expression changed significantly among the four groups. 
These genes included genes related to energy metabolism, cell proliferation, cell survival, and cell death, such 
as zinc finger protein 667 (Zfp667), phosphorylase b kinase regulatory subunit beta (Phkb), peroxisome prolif-
erative activated receptor gamma coactivator 1 alpha (Ppargc1a), pentatricopeptide repeat domain 2 (Ptcd2), 
nucleophosmin 1 (Npm1), dual specificity phosphatase 18 (Dusp18), paternally expressed gene 10 (Peg10), and 
topoisomerase (DNA) 3 alpha (Top3a) (Table 4).
Of the genes studied, we focused on Zfp667, which has been reported to suppress apoptosis-related genes 
and consequently prevent cell death in ischemia-reperfusion injury41,42. Western blot analysis of mouse retinal 
proteins showed that expression levels of Zfp667 was not significantly different between non-treated retinas 
and saline-treated NMDA-injected retinas (NMDA-saline as control) of wild-type mice (P = 0.61, Turkey HSD, 
Fig. 5a,b). In contrast, expression of Zfp667 was significantly increased in KUS121-treated NMDA-injected ret-
inas compared to the NMDA-saline group (P = 0.004, Turkey HSD, Fig. 5a,b). Immunohistochemical analysis 
with an anti-Zfp667 antibody showed higher expression of Zfp667 predominantly at the retinal ganglion cell layer 
in KUSs-treated NMDA-injected retinas compared to NMDA-saline injected retinas (Fig. 5c).
Discussion
In this study, we successfully isolated retinal ganglion cells to a high level of purity using FACS and found that 
KUSs affect the expression of a wide variety of genes. These include genes involved in the regulation of energy 
metabolism and suppression of apoptosis in the retinal ganglion cells of an NMDA-induced retinal injury model 
mouse.
There have been studies in which neural cells including retinal ganglion cells were isolated using FACS with 
retrograde labelling43,44 or with antibodies45. In the current study, we used Thy1-CFP transgenic mice29,30, in 
which CFP is expressed in retinal ganglion cells, to omit the need for antibody reaction or the retrograde labelling 
step. It enabled us to collect the cells simply and quickly, which were suitable for the analysis of mRNA profiles.
5Scientific RepoRtS |         (2020) 10:4251  | https://doi.org/10.1038/s41598-020-61160-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
In the preliminary experiments to decide the timing for evaluating gene expression after intravitreous NMDA 
injection, neural retina of wild-type mice was used. While intravitreous NMDA injection has been reported 
to damage RGCs19, whole retinas of mice that received intravitreous NMDA injection were used for mRNA 
evaluation by qRT-PCR46. Hence, we used neural retina in the preliminary experiments. Moreover, among the 
18 genes evaluated by qRT-PCR using neural retina, Jun and Fos were included in the 255 genes evaluated by 
next-generation sequencing using sorted RGCs that showed significant changes in expression among the four 
conditions. The expression of Jun and Fos genes was upregulated by 1.63 and 3.59 times, respectively, in NMDA 
treated mice RGCs compared to non-treated controls.
Our experiments showed that KUS121, which has already been used in a clinical trial for ischemic reti-
nal disease (UMIN000023979), upregulated gene expression and translation of Zfp667 in the retinal ganglion 
cells. Zfp667 has been reported to suppress apoptosis-related genes in ischemia-reperfusion injury41,42. KUS121 
also upregulated the expression of a variety of genes such as Phkb, which is involved in glycogen metabolism47; 
Ppargc1a, which is a strong activator of mitochondrial function and a regulator of energy metabolism48–50; 
Ptcd2, which is involved in mitochondrial gene expression51; Npm1, which promotes cell survival under stress52; 
Dusp18, which may dephosphorylate and inactivate mitogen-activated protein kinase (MAPK)47; Peg10, which 
is anti-apoptotic53. On the other hand, genes that were downregulated by KUS121 included Top3a, which adjusts 
the DNA topological states during transcription47. Whether the translation of these genes is also altered remains 
to be clarified. In addition to reducing ATP consumption, these results revealed the possibility that KUS121 
Figure 3. mRNA expression in retinal ganglion cells in an acute injury model. (a) Tree diagram of 
hierarchically clustered conditions. Red and green numbers show approximately unbiased p-values (AU) and 
bootstrap probability value (BP). (b) Heat map of mRNA expression of clustered conditions. Non treat: retinal 
ganglion cells of non-treated mice, NMDA-K121: retinal ganglion cells of NMDA-injected mice administered 
KUS121, NMDA-K187: retinal ganglion cells of NMDA-injected mice administered KUS187, NMDA-saline: 
retinal ganglion cells of NMDA-injected mice administered vehicle.
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prevents retinal ganglion cell death through several mechanisms, including activating energy production and 
suppression of apoptosis. These mechanisms could be related to the modulation of VCP function or alternatively, 
KUSs may have additional targets, which could be involved in transcriptional control of cell survival. These pos-
sibilities need to be elucidated by further studies.
In conclusion, KUS121 can modulate gene expression profiles in retinal ganglion cells in mice, via mech-
anisms not yet fully elucidated, which are likely to contribute to protecting the retinal ganglion cells from 
NMDA-induced neurotoxicity. This study further strengthens the suitability of KUS121 as a therapeutic drug in 
rescuing retinal ganglion cells in eye diseases that are currently incurable, such as glaucoma.
Methods
Experimental animals. This study was conducted in accordance with the Association for Research in 
Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research. All 
protocols were approved by the Institutional Review Board of Kyoto University Graduate School of Medicine 
(MedKyo 12245, 13221, 14213, 15531, 16501). B6.Cg-Tg(Thy 1-CFP) 23Jrs/J mice were obtained from the 
Jackson Laboratory (Bar Harbor, ME, USA) and wild-type mice (C57/BL6), which share the genetic background 
of Thy1-CFP mice, were purchased from Japan SLC, Inc. Mice were kept in a 14 h light/10 h dark cycle and fed 
ad libitum. Male mice aged 2 to 3 months were used for the experiments. Before intravitreous NMDA injection 
(5 nmol), mice were anesthetised with intraperitoneal pentobarbital (50 mg/kg) injection and pupils were dilated 
with tropicamide and phenylephrine eye drops (0.5% each).
Quantitative RT-PCR of neural retinae. Changes in mRNA expression in the neural retina were exam-
ined at several time points after intravitreous NMDA injection. NMDA was intravitreally injected into wild-type 
mice to induce acute damage of retinal ganglion cells17,19. Eyeballs were enucleated 2, 4, and 6 h after NMDA 



























GO:0009889 0.001332 2.9 regulation of biosynthetic process Camta1,Cir1,Csrnp2,Fos,Fosb,Gatad2a,Nr4a1,Rfc1





















GO:0009059 0.001314 2.6 macromolecule biosynthetic process Camta1,Cir1,Csrnp2,Eif2s3y,Extl1,Fos,Fosb,Gatad2a,Nr4a1,Rfc1







GO:0019438 0.006642 2.3 aromatic compound biosynthetic process Camta1,Cir1,Csrnp2,Fos,Fosb,Gatad2a,Nr4a1,Rfc1
Table 1. Top 15 gene ontology (GO) terms for genes whose upregulation by NMDA was attenuated in KUS-
treated retinal ganglion cells.
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immediately after enucleation. Incisions were made using pinholes in the corneas, then using the incisions, the 
sclera was peeled to remove the mixture of the retinal pigment epithelium, choroid and sclera from the neural ret-



















WP1251 Metapathway biotransformation 1 1 3 143 0.005723 0.004692 5.40E-09
WP317 Glycogen Metabolism 1 1 1 34 0.007623 0.006252 0.007125
WP2310 PodNet-protein-protein interactions in the podocyte 1 3 2 315 0.00952 3.61E-08 3.12E-05
WP2309
XPodNet-protein-protein 
interactions in the podocyte 
expanded by STRING
1 3 2 836 0.018951 4.31E-07 1.40E-04
Table 2. Pathways which were common in NMDA-saline group < non-treat group, KUS121 group > NMDA-
saline group and KUS187 group > NMDA-saline group (fold change > 2 or fold change < 0.5, respectively). 
saline: NMDA-saline group, K121: KUS121 group, K187: KUS187 group.
Figure 4. Glycogen metabolism Pathway activation in KUS-treated retinal ganglion cells. Pathway analysis of 
genes which were upregulated (fold change > 2) or downregulated (fold change < 0.5) between groups were done 
using an analysis software, Gene Spring14 (TOMY Digital Biology, http://genespring-support.com/). Pathways 
that were common in NMDA-saline < non-treat, KUS121 > NMDA-saline and KUS187 > NMDA-saline included 
glycogen metabolism pathway. Genes included in the current analysis, which passed p < 0.01 with analysis of 
variance (255 genes), are shown in orange color boxes. The bar graph next to the genes in the orange color boxes 
show the normalized expression values (N: non-treat, S: NMDA-saline, 121: KUS121, 187: KUS187). Phkb was 
an only gene which passed the upregulated and downregulated criteria above; downregulated in NMDA-saline 
compared to non-treat and was upregulated in KUS121 and KUS187 compared to NMDA-saline. The gene is 
shown in red frame box. non treat: retinal ganglion cells of mice without NMDA injection nor KUS treatment, 
NMDA-saline: retinal ganglion cells of NMDA-injected mice administered vehicle, KUS121: retinal ganglion 
cells of NMDA-injected mice administered KUS121, KUS187: retinal ganglion cells of NMDA-injected mice 
administered KUS187. In fold change analysis, >2 indicates more than 2 folds while <0.5 indicates less than 0.5 
fold. For pathway analysis, A < B means statistically significant pathways of genes that were downregulated in 
group A by less than 0.5 fold compared to group B, and A > B means statistically significant pathways of genes that 
were upregulated in group A by more than 2 folds compared to group B.
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RNeasy Mini Kit (QIAGEN, Venlo, Netherlands). The mRNA was reverse transcribed with the M-MLV reverse 
transcriptase (Promega, WI, USA) and then complementary DNA was amplified by PCR with SYBR premix Ex 
Taq polymerase (Takara Bio Inc., Shiga, Japan) and 60 °C as the annealing temperature on the 7300 Real-Time 
PCR System (Applied Biosystems, CA, USA). Eyes were enucleated before and 2, 4 and 6 h after NMDA injection 
and each eye was analysed separately.
The levels of the following mRNAs were analysed by qRT-PCR: Nfkbia, Il6, Rela, Casp3, Fos, Mapk1, Mapk3, 
Mapk10, Jun, Tnf, Akt1, Akt2, Fis1, Mfn1, Mfn2, Dnm1l, Opa1, Hmgb1 (primers used are shown in Supplementary 
Table S3). Actin was used as the internal standard.
Administration of KUSs and preparation of cell suspension for flow cytometry. Daily KUS121, 
KUS187 (50 mg/kg/day each), or vehicle (5% Cremophor EL (Sigma) in phosphate buffered saline (PBS)) as 
a control were given orally to Thy1-CFP mice using a feeding tube. Seven days after the start of the medica-
tion, NMDA (5 nmol) was intravitreally injected with a 33-gage needle54. Our experiment involved one-week 
pre-treatment with KUSs because we previously showed that it protects against NMDA injury17. Four hours 
after the NMDA injection, the retinas were collected as described in the qRT-PCR section and incubated in 0.2% 
papain solution (two retinas of two mice each) including glucose (1 mg/mL), DNase 1 (Worthington, 100 U/mL), 
superoxide dismutase (Worthington, 5 µg/mL) and catalase (Sigma, 5 µg/mL) at 8 °C for 30 min and at 28 °C for 
9 min. The solution was centrifuged at 100 G for 5 min at 4 °C, cells were resuspended in a solution containing 
antipain (Roche, 50 µg/mL), and then centrifuged again at 100G for 5 min at 4 °C55. The cell pellet was resus-
pended in 500 µL of ice-cold Ames’ medium (with L-glutamine, without sodium bicarbonate, Sigma).
Collection of retinal ganglion cells by flow cytometry. The cells in suspended Ames’ medium 
described above were sorted by FACS Aria 2 (BD Biosciences) based on the size and intensity of CFP fluores-




















protein interactions in 
the podocyte
3 1 1 315 1.14E-07 0.008276 0.017887
WP2309
XPodNet-protein-
protein interactions in 
the podocyte expanded 
by STRING










1 1 1 104 0.004569 0.003318 0.007193





1 1 1 31 0.006846 0.004974 0.010771
WP1266 SIDS Susceptibility Pathways 1 1 2 61 0.006846 0.004974 3.85E-05
Table 3. Pathways which were common in NMDA-saline group > non-treat group, KUS121 group < NMDA-
saline group and KUS187 group < NMDA-saline group (fold change > 2 or fold change < 0.5, respectively). 
saline: NMDA-saline group, K121: KUS121 group, K187: KUS187 group.
Description (possible) Function
Zfp667 may play a role in protecting cells against ischemia-reperfusion injury41,42
Phkb plays a role in glycogen metabolism47
Ppargc1a activate mitochondrial function48–50
Ptcd2 plays a role in post-transcriptional expression of the mitochondrial genome51
Npm1 enhances cell survival under stress conditions52
Dusp18 inactivate MAP kinases47
Peg10 promote growth and suppress apoptosis53
Top3a adjust the DNA topological states47
Table 4. Focused genes which were significantly changed between KUS-treated and control retinal ganglion 
cells.
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sorting was performed using a 85-micron nozzle into Ames’ medium at 4 °C. Forward scatter (FSC) and sideward 
scatter (SSC) were used to segregate retinal ganglion cells. CFP-positive cells were contained in the high FSC 
sub-population (area 2 in Supplementary Fig. S1a). To collect retinal ganglion cells with high purity, only cells 
included in both gate 4 (Supplementary Fig. S1b), which is a smaller area than area 2, and gate 5 (Supplementary 
Fig. S1c), which was narrower than the area 1 in Fig. 2a–c, were collected (gate RGCs). For comparison, cells 
included in both gate 6 (Supplementary Fig. S1b) and gate 7 (Supplementary Fig. S1c), which were considered to 
be photoreceptors, were collected in the same way (gate PR).
cDNA synthesis, amplification and next-generation sequencing. The sorted cells (1,494–7,848 cells 
for each sample) were centrifuged at 500G for 5 min at 4 °C, suspended in 100 µL of buffer B (Prelude Direct Lysis 
Module, NuGEN), centrifuged again at 500G for 5 min at 4 °C, and the pellet was resuspended in 1 µL of buffer A 
(Prelude Direct Lysis Module, NuGEN). The lysates were then taken forward for cDNA synthesis and amplifica-
tion using Ovation RNA-Seq System V2 (NuGEN) according to the manufacturer’s instructions. The amplified 
cDNA was purified using MinElute Reaction Cleanup Kit (QIAGEN, Venlo, Netherlands). The quality of the 
amplified cDNAs was analyzed by a 2100 Bioanalyzer (Agilent) and was high enough for sequencing. The concen-
tration of cDNA as measured by Qubit (Invitrogen) was sufficient (84.7–185.0 ng/µL). The amplified cDNA was 
then sequenced with a next-generation sequencer (Illumina HiSeq). The experiments were repeated three times.
Analysis of the RNA-sequencing results. The results of RNA-sequencing were mapped on reference 
sequence (mouse mm10, USCS genome browser) using TopHat2. Reads which formed reasonable pairs (on the 
same chromosome, two directionally, and distance between pair reads < 500 k b.p.) were used to calculate expres-
sion levels (61.1 ± 8.5% of reads). Reads Per Kilobase of exon model per 10 Million mapped reads (RPK10M) 
Figure 5. Increased expression of Zfp667 in KUS121-treated retinal ganglion cells. (a) Western blot analysis 
of NMDA-injected mice retinas with KUS121 (labelled as “K”) or vehicle (NMDA-saline as control, labelled 
as “C”) administration with a zing finger protein (ZFP667) antibody. Actin was used as a loading control. WT: 
wild-type mouse retina. Complete scans of western blots are shown in Supplementary Fig. S4. (b) Comparison 
of ZFP667 expression shown as ratio of actin. **P < 0.01, Turkey HSD. (c) Vertical retinal sections of mouse 
retina were stained with anti-ZFP667 antibody (red). Fluorescence intensity of the complex of RNFL, GCL 
and IPL was measured. Control: NMDA-injected mouse retina with saline administration, KUS121: NMDA-
injected mouse retina administered KUS121, KUS187: NMDA-injected mouse retina administered KUS187, 
WT: wild-type mouse retina without NMDA injection or KUSs administration. RNFL: retinal nerve fiber layer; 
GCL: ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; OPL: outer plexiform layer; ONL: 
outer nuclear layer; IS: inner segment of photoreceptors, and OS: outer segment of photoreceptors. Scale bar: 
50 µm.
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were calculated for terminal exons with the in-house scripts as the expression values for genes, and transferred 
into log2 scale. Genes whose maximum expression values were more than 3 among the conditions were consid-
ered as expressed genes and used for the following analyses. Then the expression value was normalized using 
quantile normalization methods56. Using analysis of variance (ANOVA), 255 genes (including isoforms) showed 
significant changes in expression among the four conditions (non-treat, NMDA-saline, KUS121 and KUS187, 
p < 0.01). Hierarchical clustering of the 255 genes that passed the ANOVA test with approximately unbiased 
p-values and bootstrap probability value of mRNA expression was performed with pvclust package in the sta-
tistical environment R using Euclidean distances. A heatmap was drawn with Z-value transferred expression 
values. Expression profiles of ANOVA-passed genes were transferred to Z-scores and clustered with the x-means 
method. X-means clustering was performed on the statistical environment R. The genes were divided into 12 
clusters that were further categorized according to expression changes across conditions. The upregulation and 
downregulation of gene expression were defined as the difference in the cluster centers between conditions with 
more than 0.2 and less than −0.2 z-values, respectively (Supplementary Fig. S3). The clusters with upregulated 
expression in NMDA-saline compared to non-treat and downregulated expression in KUS121 and KUS187 
compared to NMDA-saline were defined as hyper cluster A. The clusters whose expression was upregulated in 
NMDA-saline compared to non-treat and whose expression was upregulated in KUS121 and KUS187 compared 
to NMDA-saline, were defined as hyper cluster B. GO analysis of the genes included in hyper cluster A (55 genes) 
and B (12 genes) was performed based on hypergeometric distribution.
Pathway analysis was performed by Gene Spring14 (TOMY Digital Biology) using Wiki Pathways (http://
www.wikipathways.org/index.php/WikiPathways). Genes that were upregulated (115 genes) or downregu-
lated (57 genes) in the NMDA-saline group compared to the non-treat group, and those that were upregulated 
(61 genes) or downregulated (73 genes) in the KUS121 group compared to the NMDA-saline group as well as 
upregulated (50 genes) or downregulated (53 genes) in the KUS187 group compared to the NMDA-saline group 
(fold change > 2 or fold change < 0.5, respectively) were analyzed. The level of statistical significance was set to 
P < 0.05.
In fold change analysis, >2 indicates more than 2 folds while <0.5 indicates less than 0.5 fold. For pathway 
analysis, A < B means statistically significant pathways of genes that were downregulated in group A by less than 
0.5 fold compared to group B, and A > B means statistically significant pathways of genes that were upregulated 
in group A by more than 2 folds compared to group B.
Immunocytological evaluation of cells. Dissociated retinal cells or FACS sorted cells were fixed by 
adding an equal amount of 4% paraformaldehyde, centrifuged at 3000 rpm for 15 min at 4 °C. After the extra 
supernatant was removed, the cell suspension (200 µL) was centrifuged at 1000 rpm for 10 min using Cytospin 
(Thermo Scientific) to be pasted onto slides. The cells were stained with anti-Brn3a (CHEMICON) and anti-Pax6 
(COVANCE) antibodies and imaged under an optical microscope (Axio Imager.A1, Zeiss).
Immunohistological evaluation of retinas. Non-treated eyeballs or NMDA-injected eyeballs of mice 
treated with KUS121, KUS187 or vehicle (saline) were enucleated after pentobarbital overdose. A marking dye 
(Davidson) was placed on the edge of the superior conjunctiva to identify the superior portion of the retina as 
previously described57. The eyes were fixed in 4% paraformaldehyde for 24 h at 4 °C, embedded in O.C.T. com-
pound (Sakura Finetek Japan) and frozen. Serial 16 µm O.C.T-embedded sections were cut through the dye and 
at the point of insertion of the optic nerve. Sections that included the center of the optic nerve head were stained 
with an anti-ZFP667 antibody (GeneTex) and imaged under an optical microscope (BZ-9000, Keyence) at a 
distance of 400 µm from the edge of the optic nerve head. The fluorescence intensity of each eye was measured in 
40 µm × 300 µm squares including the retinal nerve fiber layer, the ganglion cell layer, and the inner plexiform 
layer using BZ II Analyzer software (Keyence).
Western blotting of neural retinas. Neural retinas were prepared as described in the qRT-PCR sec-
tion. Neural retinas and wild-type mouse brain, which was used as a positive control, were analysed with an 
anti-ZFP667 antibody (GeneTex). Actin was used as a loading control. The ratio of ZFP667 to actin was compared 
between the KUS121-treated and the control retina using an unpaired t-test.
Data availability
All data generated or analyzed during this study are included in this published article and its Supplementary 
Information files.
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